REHOVOT, Israel, Sept. 15, 2022 (GLOBE NEWSWIRE) -- Pharma Two B Ltd. today announced that positive efficacy and safety data from its recently completed randomized, controlled Phase 3 trial of investigational P2B001 in the management of early PD will be presented at the MDS International Congress of Parkinson's Disease and Movement Disorders® Sept. 15-18 in Madrid. The data will be presented in various formats, including a guided poster tour, an e-poster and video on the MDS Congress virtual platform, and publication in the Movement Disorders journal supplement.
REHOVOT, Israel, April 05, 2022 (GLOBE NEWSWIRE) -- Pharma Two B Ltd., a privately held company developing innovative therapeutics based on reformulation and combinations of previously approved...
REHOVOT, Israel, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Pharma Two B Ltd., a privately held company developing innovative therapeutics for neurological indications, today announced that it will host a key opinion leader (KOL) event to discuss the positive results from the pivotal Phase III Study of P2B001 in early Parkinson’s Disease (PD) on Thursday, January 27, 2022 from 11am – 12pm Eastern Time.